Rein Therapeutics
RNTX
19 hedge funds and large institutions have $1.3M invested in Rein Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 19 → 19 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
6.74% less ownership
Funds ownership: 29.89% → 23.14% (-6.7%)
59% less capital invested
Capital invested by funds: $3.21M → $1.3M (-$1.91M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$41.5K |
| 2 |
HF
HRT Financial
New York
|
+$25K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$22.1K |
| 4 |
Renaissance Technologies
New York
|
+$4.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.95K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$561K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$153K |
| 3 |
William Blair & Company
Chicago,
Illinois
|
-$76.4K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$6.88K |
RNTX Hedge Fund Activity: Q1 2023 in Review
19 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q1 2023, worth a combined $1.3M — down 59% from $3.21M a quarter earlier.
Fund positioning in RNTX was balanced in Q1 2023: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 4 trimmed.
The largest buyer was HighTower Advisors, opening a new position worth an estimated $41.5K. The largest seller was BVF Inc, exiting entirely with an estimated $561K sold.
- 19 institutional investors held Rein Therapeutics (RNTX) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $1.3M of Rein Therapeutics stock for Q1 2023, down 59% quarter-over-quarter.
- 3 funds opened new Rein Therapeutics positions in Q1 2023 and 3 closed out, a net change of 0 holders.
- The largest Rein Therapeutics buyer in Q1 2023 was HighTower Advisors, an estimated $41.5K added.
- The largest Rein Therapeutics seller in Q1 2023 was BVF Inc, an estimated $561K sold.
Based on aggregated 13F filings for Q1 2023.